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Abstract
Background Systems for determining psoriasis severity in clinical trials have not been sufficiently validated against
patients’ perceived quality of life.
Objective To validate three systems of physician-determined psoriasis severity (the Lattice System Physician’s Global
Assessment [LS-PGA], Psoriasis Area and Severity Index [PASI] and static Physician’s Global Assessment [sPGA]).
Methods Data were from a 24-week randomized, double-blind, placebo-controlled, multicenter trial of therapy with oral
calcineurin inhibitors in 445 patients. Construct validity was measured by correlations of the three severity scores with
patients’ self-reported quality of life (QoL) from the Dermatology Life Quality Index (DLQI) and a DLQI item about psoria-
sis symptoms.
Results All severity systems were moderately and positively correlated with QoL, indicating construct validity. QoL
was most consistently related to physicians’ assessments of body surface area involved with psoriasis (iBSA) followed
by, in the order of consistency, plaque elevation, erythema and scale.
Conclusions The LS-PGA weights iBSA and aspects of plaque morphology in concert with their relative effects on
QoL. The LS-PGA, sPGA and PASI are validated by their relationship to QoL in a clinical trial.
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Introduction
A systematic review1 enumerated 53 systems for evaluating pso-
riasis severity in clinical trials. Because there is no agreed-upon
gold standard for measuring the degree of severity of psoriasis,
the validity of systems that assesses psoriasis severity cannot be
established solely by comparing one system to another. There-
fore, in this study, we validated scoring systems against patients’
reported quality of life (QoL).2,3
Construct validation is especially important in the absence of
an accepted standard. Construct validity is the extent to which a
measuring system that quantifies a specific concept is associated
with other measures that are expected to be related to that†Both authors contributed equally to this work.
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concept. If our measuring systems have construct validity in
assessing ‘psoriasis severity’, we expect them to be associated
with other measures related to severity, such as QoL of patients
with psoriasis.
We used data made available to us from a phase III clinical
trial to investigate the validity of the Lattice System Physician’s
Global Assessment (LS-PGA), Psoriasis Area and Severity Index
(PASI) and static Physician’s Global Assessment (sPGA) as clini-
cal measures of psoriasis severity. The degree to which a decrease
in disease severity (i.e. lower scores in each of the three clinical
scoring systems) is associated with skin-related QoL improve-
ment (i.e. lower scores in the Dermatology Life Quality Index
[DLQI]) is an indication that a system has construct validity.
Content validity is the extent to which the individual compo-
nents of a composite scoring system are related to the overall
concept, e.g. psoriasis severity. We used the percentage of the
patient’s involved body surface area (iBSA) and the overall eleva-
tion, erythema and scale of the psoriasis plaques in a multiple
regression analysis with DLQI to assess the relative impact of
each individual component of a psoriasis severity scoring system
on QoL. In addition, we wanted to find out whether the relative
weighting of the components of psoriasis to obtain the final
score in the LS-PGA algorithm conformed to another measure
of psoriasis severity, namely QoL.
Patients, materials and methods
Study design
This observational study utilizes data from a randomized, dou-
ble-blind, multicentre, phase III clinical trial (ClinicalTrials.gov,
NCT00408187). For this study, we included only the 445
patients, age 18 or over, who had complete severity and QoL data
at pretherapy, week 12 and week 24. Subjects were randomized in
a 3:1:1 fashion to receive divided doses of voclosporin 0.8 mg/kg/
day or cyclosporine 3.0 mg/kg/day (‘24-week-treatment’ group) or
placebo (‘initial-placebo’ group). By protocol, all patients ran-
domized to the placebo group crossed over to voclosporin ther-
apy at week 12. At pretherapy, week 12, and week 24, physicians
determined sPGA and provided data to calculate PASI4 and
LS-PGA5 (DATAcquire, Inc., Ann Arbor, MI, version 6.0) scores.
Whenever possible, the same investigator at each site evaluated
and scored the patients’ severity of psoriasis throughout the trial
using all three measurement systems. Patients completed the
DLQI6 at all three visits. Study investigators adhered to the
Guideline for Good Clinical Practice, which is based on the Dec-
laration of Helsinki. For additional details, see Chow et al.;7 our
study population is the same, except for the exclusion here of ten
subjects who did not have complete data for the DLQI.
Lattice System Physician’s Global Assessment
Each aspect of plaque morphology (elevation, erythema, and
scale) is scored on a defined 4-point ordinal scale ranging from
‘none’ to ‘marked’; iBSA is organized into six anchored ranges.
An algorithm integrates the defined ranges of iBSA with plaque
morphology to produce a score on an 8-point ordinal scale rang-
ing from ‘clear’ to ‘very severe’.5 In determining the final
LS-PGA score, iBSA defines a range of the final score, and
among the three elements of plaque morphology, more weight is
given to plaque elevation (the hallmark of disease activity and
least influenced by external factors), some weight to erythema,
and least weight to scale.7
Psoriasis Area and Severity Index
The body is divided into four portions [head (h), trunk (t),
upper (u) and lower (l) extremities], a score for surface area
involved (A) and lesion characteristics [erythema (E), infiltra-
tion (I), and desquamation (D)] for each of the four areas are
entered into the formula 0.1(Eh + Ih + Dh)Ah + 0.2
(Eu + Iu + Du)Au + 0.3(Et + It + Dt)At + 0.4(El + Il + Dl)Al to
calculate a score from 0 to 72.4,7
Static Physician’s Global Assessment
The sPGA in this study is an ordinal rating system ranging from
0 to 5. The investigator assessed the severity of three characteris-
tics of each patient’s psoriatic plaques (induration, erythema,
and scaling (IES)] averaged over all lesions. Equal weight was
given to each component in determining the overall sPGA score;
the investigator was instructed to assign an sPGA of 0 if IES were
all 0, 1 if all IES were at least 1, 2 if all IES were at least 2, and so
on.7
Dermatology Life Quality Index
The DLQI consists of ten questions dealing with the patient’s
perceptions of how his or her skin condition is affecting his or
her QoL.6 Each item is rated on an ordinal scale of 0 to 3 leading
to an overall (summed) score ranging from 0 to 30; higher scores
indicate a greater adverse impact on QoL. We utilized the overall
DLQI score from all ten questions and also assessed responses to
Question 1, which is the only question directly about skin symp-
toms of psoriasis, inquiring about how itchy, sore, painful or
stinging the patient’s skin has been.
The DLQI has been used extensively in psoriasis research.
Construct validity of the DLQI has been established with gen-
eric, dermatologic-specific and disease-specific measures in over
35 studies. Furthermore, test-retest reliability and internal con-
sistency have been shown to be high in multiple studies.8
Statistical analysis
For analysis, we assigned numerical scores for LS-PGA and sPGA
as in Chow et al.7 To analyse the associations between the three
clinical measures and the patient-reported skin-related QoL, we
calculated Kendall–Stuart’s tau-c9 at each time point between
each of the clinical severity scores and the total DLQI score and
the score for DLQI Question 1 for symptoms. Kendall–Stuart’s
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tau-c is a useful measure of correlation for ordinal variables with
appreciable ties and large contingency tables. Additionally, we
calculated tau-c between the change in each severity score and
the change in the DLQI score from pretherapy to week 24.
We used multiple linear regression analysis to investigate the
relation between the iBSA or plaque characteristics (erythema,
elevation, and scale) and the DLQI score. We used components
of the LS-PGA because they are scored by the physician for the
patient’s entire body. Because erythema, elevation and scale were
scored on a 4-point ordinal scale in the LS-PGA, we also catego-
rized iBSA as a 4-point ordinal scale by condensing the LS-PGA
ranges of iBSA into the following groups: 0%, 1% to 9%, 10% to
29% and >29%. A model was fitted to patients in the 24-week-
treatment or initial-placebo groups at each of the three time
points (6 models) with the four aspects of psoriasis as predictors.
Analyses used SAS version 9.2.1 (SAS Institute, Cary, NC, USA).
Results
Of the 445 subjects with complete data, 360 were randomized to
the 24-week-treatment group and 85 to the initial-placebo
group; the groups were similar (Table 1). All three psoriasis
severity scores were positively correlated (Table 2) with the total
DLQI score and with the score for certain skin symptoms (Item
1 of the DLQI that inquires about how itchy, sore, painful or
stinging the patient’s skin has been in the prior 7 days). The cor-
relations among the QoL measures and the severity scores were
weak at pretherapy (tau-c = 0.08–0.32) but higher at week 12
and week 24 (tau-c = 0.25–0.54). The change in each severity
score was positively correlated with the change in DLQI score
from pretherapy to week 24 (tau-c = 0.22–0.34, Table 3).
Table 4 presents the coefficients from the multiple linear
regression models that estimate the impact of scale, erythema,
elevation and iBSA as predictors on the DLQI score at each
observation. Each value represents the estimated mean difference
in the DLQI score for a one-category increase in the LS-PGA
score of iBSA or plaque scale, erythema or elevation. The most
consistent positive predictor of DLQI score was iBSA. During
active therapy, elevation had a greater impact than erythema.
Throughout the study, scale was only weakly and often inversely
associated with the QoL score.
Discussion
Construct validity
Because they address common and important signs of psoriasis,
all three measures appear to measure psoriasis severity (i.e. they
have face validity). Using data from a phase III clinical trial, each
of the physician-scoring systems also demonstrated construct
validity in determining psoriasis severity. That is, the measures
of psoriasis severity are positively correlated with measures of
QoL prior to and especially during and at the conclusion of a
clinical trial (Table 2). We would not expect perfect correlation
(tau-c = 1) between physician-determined severity scores and
the patient’s self-rated QoL because they reflect different under-
lying constructs. However, our moderate positive correlations
indicate that when psoriasis severity is lower as measured by the
physician rating systems, this occurs in concert with better skin-
related patient QoL. Additionally, the change in psoriasis sever-
ity during the trial was positively correlated with the change in
QoL score (Table 3), again indicating that as psoriasis severity
decreases by physician measures, it is associated with QoL
improvement among patients.
Table 1 Distribution of clinical psoriasis severity and QoL scores
at pretherapy, by assigned treatment group. There were no signifi-
cant differences in pretherapy characteristics between the
24-week-treatment group (patients who received active therapy
throughout the study) and initial-placebo group (patients who
received placebo for 12 weeks and active therapy for 12 weeks).
Psoriasis Area and Severity Index has a range of 0–72. Lower val-
ues of DLQI indicate better QoL. Based on others’ sugges-
tions,10,11 we divided PASI and DLQI into the segments shown.
Total (n = 445) 24-Week-
Treatment
(n = 360)
Initial-Placebo
(n = 85)
Psoriasis Area and Severity Index, mean (SD)
18.5 (7.0) 18.6 (7.1) 18.0 (6.4)
Ranges of Psoriasis Area and Severity Index, n (%)
<7 0 (0) 0 (0) 0 (0.0)
7–12 71 (16) 57 (16) 14 (16)
>12 374 (84) 303 (84) 71 (84)
Static Physician’s Global Assessment, n (%)
0 0 (0) 0 (0) 0 (0)
1 0 (0) 0 (0) 0 (0)
2 3 (1) 3 (1) 0 (0.0)
3 254 (57) 202 (56) 52 (61)
4 170 (38) 137 (38) 33 (39)
5 18 (4) 18 (5) 0 (0)
Lattice System Physician’s Global Assessment, n (%)
Clear 0 (0) 0 (0) 0 (0)
Almost-clear 0 (0) 0 (0) 0 (0)
Mild 0 (0) 0 (0) 0 (0)
Mild to Moderate 0 (0) 0 (0) 0 (0)
Moderate 13 (3) 10 (2) 3 (4)
Moderate to Severe 122 (27) 98 (27) 24 (28)
Severe 193 (43) 159 (44) 34 (40)
Very Severe 117 (26) 93 (26) 24 (28)
Dermatology Life Quality Index, mean (SD)
11 (6) 11 (6) 11 (7)
Ranges of Dermatology Life Quality Index, n (%)
0–1 164 (37) 159 (44) 5 (6)
2–5 128 (29) 103 (29) 25 (29)
6–10 86 (19) 66 (18) 20 (24)
11–20 59 (13) 30 (8) 29 (34)
21–30 8 (2) 2 (1) 6 (7)
SD, standard deviation.
© 2015 European Academy of Dermatology and VenereologyJEADV 2015, 29, 1415–1420
Quality of life and psoriasis severity 1417
The correlations for all three clinical severity scores and QoL
are considerably stronger at weeks 12 and 24 than at pretherapy
(Table 2). This pattern, similar to that reported by Shikiar
et al.,12 is probably due to reduced variability in psoriasis sever-
ity at pretherapy because of the effects of enrolment criteria that
narrow the range of patient severity at the initial visit. Because
correlation coefficients are variance-based measures of associa-
tion, the smaller variance in psoriasis severity relative to DLQI
variance at pretherapy results in a lower correlation compared to
later visits, even when the linear relation (slope) remains con-
stant. Similarly, the correlation between Item 1 of the DLQI and
each overall severity score is stronger at weeks 12 and 24 than at
pretherapy.
Psoriasis of equal severity (as rated by physicians) conforms
to a range of patient-reported QoL scores and symptoms. Clini-
cians are familiar with patients who have large amounts of psori-
asis yet are unfazed; conversely, some patients are deeply
troubled by relatively few areas of involvement. These examples
support the role of investigating measures of both QoL and clin-
ical psoriasis severity in research studies; they capture distinct
information.13,14 Nevertheless, in large groups of patients with
psoriasis in clinical trials, QoL is closely related to clinical sever-
ity.15 We are unaware of any clinical trial in which clinical sever-
ity scores improved overall without concomitant improvement
in overall QoL.
Content validity
Using patients’ self-reports of skin-related QoL, we investigated
the content validity of the physician-measured extent of psoriasis
involvement and plaque morphology. We found that iBSA was
the attribute of psoriasis that most consistently associated with
DLQI scores. Thus, it may surprise that the sPGA does not
incorporate any assessment of iBSA. In contrast, iBSA is the
primary component of the LS-PGA algorithm and an important
aspect of the PASI calculation.4,5
The amount of scale on the psoriasis plaques as determined
by the physician was minimally and inconsistently associated
with DLQI scores. Although patients may mention scale as part
of the disease process that adversely affects their life, the physi-
cian rating of scale is not a good predictor of the patient’s QoL
(Table 4). This may be in part because scale varies with factors
such as skin hydration, application of topical moisturizers or
ambient conditions. Furthermore, the amount of scale as a static
measure at a patient visit may not reflect scaling (the flaking off)
that may be even more distressing to patients.
In contrast to scale, elevation and erythema were positively asso-
ciated with the DLQI score at all observations, although the associ-
ations were not consistently strong, particularly at pretherapy
(Table 4). With active therapy, change in plaque elevation had
more effect on QoL than did erythema. When translating these
Table 2 Correlation between the Lattice System Physician’s Global Assessment (LS-PGA), Psoriasis Area and Severity Index (PASI) and
static Physician’s Global Assessment (sPGA) scores and the Dermatology Life Quality Index (DLQI) score and the DLQI symptom severity
question at pretherapy, week 12, week 24 and by the assigned treatment group. Question 1 of the DLQI inquires about how itchy, sore,
painful or stinging the patient’s skin has been in the prior seven days.
LS-PGA PASI sPGA
24-Week-
Treatment
(n = 360)
Initial-Placebo*
(n = 85)
24-Week-
Treatment
(n = 360)
Initial-Placebo*
(n = 85)
24-Week-
Treatment
(n = 360)
Initial-Placebo*
(n = 85)
Pretherapy
DLQI 0.10† 0.32† 0.14† 0.15 0.13† 0.26†
Question 1 0.08 0.13 0.13† 0.10 0.12† 0.17
Week 12
DLQI 0.43† 0.35† 0.40† 0.40† 0.39† 0.41†
Question 1 0.44† 0.42† 0.45† 0.54† 0.39† 0.43†
Week 24
DLQI 0.41† 0.41† 0.38† 0.36† 0.37† 0.29†
Question 1 0.38† 0.44† 0.42† 0.44† 0.37† 0.25†
*Initial-Placebo group crossed over to active therapy at week 12.
†P < 0.05 from testing the null hypothesis that there is no association (tau-c = 0).
Table 3 Correlation between change in the Lattice System Physi-
cian’s Global Assessment, Psoriasis Area and Severity Index, and
static Physician’s Global Assessment scores and the change in
the Dermatology Life Quality Index score from pretherapy to week
24, by assigned treatment group (n = 445)
24-Week-Treatment
(n = 360)
Initial-Placebo*
(n = 85)
Lattice System Physician’s
Global Assessment
0.23 0.32
Psoriasis Area and
Severity Index
0.22 0.24
Static Physician’s Global
Assessment
0.23 0.34
*Initial-Placebo group crossed over to active therapy at week 12.
P < 0.05 for all values.
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findings to the validation of scoring systems, a scoring system that
weights elevation, erythema, and scale equally would not capture
the varying degrees to which these factors affect the patient’s rating
of QoL. PASI and sPGA have equal weighting for all characteris-
tics; the LS-PGA weights elevation, erythema and scale5 in concert
with their relative associations with QoL.
Our study benefited from the large sample size and longitudi-
nal design. Subjects were examined three times during the study
– when all were not under treatment, when some had been on
active treatment for 12 weeks and when all subjects had been on
active treatment for at least 12 weeks. Thus, we have data from
subjects with varying psoriasis severity at various times on treat-
ment.
Hampering any study of the validity of measures of psoriasis
severity is the lack of a ‘gold-standard’ for determining the sever-
ity of psoriasis and response to treatment. While this is an inher-
ent limitation with no known remedy, it means we must rely on
assessments of construct validity to evaluate and compare sever-
ity measures. We used the DLQI, the most widely used measure
of QoL in dermatology studies, as a validated measure of skin-
related QoL to establish the construct validity of physician-
determined measures of severity.16,17 In this clinical trial, the
DLQI was the only evaluation of QoL; thus, our analysis was
limited to the DLQI, and we chose Question 1 from the DLQI
because of its relevance to psoriasis severity measurement sys-
tems. Other measures of QoL exist, and some are specific to
psoriasis; we hope that large clinical trials that utilize other meas-
ures of QoL may become available to us or other researchers in
future. Because more than 95% of the patients in the trial were
white, our results may not generalize to all patients.
When choosing a severity measure for a clinical trial of psori-
asis patients, a measure that is known to be reliable, valid and
responsive to changes in severity is desired. Because patients put
trust in their dermatologists’ treatment recommendations with
the hope of years of improved QoL, it is important to have valid
measures so that physicians may choose therapeutic approaches
based on interpretable clinical trial results. Although there are
various reasons for choosing among rating systems of psoriasis
severity in clinical trials,7 our results indicate that the measure-
ment of extent of psoriasis (i.e. iBSA) should be an important
component of the evaluation method because of its relevance to
patients’ QoL. Similarly, appropriate weighting of psoriasis
plaque components (e.g. elevation, erythema and scale), such as
that which occurs in the LS-PGA, may aid in determining a clin-
ical severity score that closely corresponds to the quality of life
of patients with psoriasis.
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